Effectiveness of tofacitinib in patients with ulcerative colitis: an updated systematic review and meta-analysis of real-world studies
Objectives This study aimed to evaluate the real-world effectiveness of tofacitinib for treating moderate-to-severe ulcerative colitis (UC).Design Systematic review and meta-analysis.Data sources PubMed, EMBASE and Cochrane CENTRAL databases were searched from inception up to 18 July 2023. Reference...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2024-12-01
|
| Series: | BMJ Open Gastroenterology |
| Online Access: | https://bmjopengastro.bmj.com/content/11/1/e001347.full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1846118433838596096 |
|---|---|
| author | Chuan Wan Chien-Hung Lin Wen-Sheng Liu Hsin-Hui Wang |
| author_facet | Chuan Wan Chien-Hung Lin Wen-Sheng Liu Hsin-Hui Wang |
| author_sort | Chuan Wan |
| collection | DOAJ |
| description | Objectives This study aimed to evaluate the real-world effectiveness of tofacitinib for treating moderate-to-severe ulcerative colitis (UC).Design Systematic review and meta-analysis.Data sources PubMed, EMBASE and Cochrane CENTRAL databases were searched from inception up to 18 July 2023. Reference lists of included studies were manually searched to identify potentially relevant studies not found in the databases.Eligibility criteria Eligible studies included real-world observational studies, reported in English, on patients with moderate-to-severe UC treated with tofacitinib, defined by the Partial Mayo Score. Excluded were clinical trials, reviews, letters, conference abstracts, case reports and studies involving patients with mixed Crohn’s disease.Data extraction and synthesis Two independent reviewers extracted data and recorded it in Excel. Quality assessment was performed using the Newcastle-Ottawa scale. Meta-analysis was performed using random-effects models due to high heterogeneity across studies.Results 19 studies containing a total of 2612 patients were included. Meta-analysis revealed that clinical response rates were 58% at week 8, 61% at weeks 12–16, 51% at weeks 24–26 and 51% at week 52. Clinical remission rates were 39% at week 8, 43% at weeks 12–16, 40% at weeks 24–26 and 43% at week 52. Corticosteroid-free clinical remission rates were 33% at week 8, 37% at weeks 12–16, 32% at weeks 24–26 and 40% at week 52.Conclusion This meta-analysis of real-world studies indicates that treatment of UC with tofacitinib is associated with favourable clinical response and remission rates in the induction and maintenance phases. |
| format | Article |
| id | doaj-art-3c4c19b6c0f64d36b3024c1ec9d4e3c7 |
| institution | Kabale University |
| issn | 2054-4774 |
| language | English |
| publishDate | 2024-12-01 |
| publisher | BMJ Publishing Group |
| record_format | Article |
| series | BMJ Open Gastroenterology |
| spelling | doaj-art-3c4c19b6c0f64d36b3024c1ec9d4e3c72024-12-17T18:55:09ZengBMJ Publishing GroupBMJ Open Gastroenterology2054-47742024-12-0111110.1136/bmjgast-2024-001347Effectiveness of tofacitinib in patients with ulcerative colitis: an updated systematic review and meta-analysis of real-world studiesChuan Wan0Chien-Hung Lin1Wen-Sheng Liu2Hsin-Hui Wang3Department of Pediatrics, Taipei City Hospital Zhongxing Branch, Taipei, TaiwanDivision of Pediatric Immunology and Nephrology, Department of Pediatrics, Taipei Veterans General Hospital, Taipei, TaiwanSchool of Medicine, National Yang Ming Chiao Tung University, Taipei, TaiwanDivision of Pediatric Immunology and Nephrology, Department of Pediatrics, Taipei Veterans General Hospital, Taipei, TaiwanObjectives This study aimed to evaluate the real-world effectiveness of tofacitinib for treating moderate-to-severe ulcerative colitis (UC).Design Systematic review and meta-analysis.Data sources PubMed, EMBASE and Cochrane CENTRAL databases were searched from inception up to 18 July 2023. Reference lists of included studies were manually searched to identify potentially relevant studies not found in the databases.Eligibility criteria Eligible studies included real-world observational studies, reported in English, on patients with moderate-to-severe UC treated with tofacitinib, defined by the Partial Mayo Score. Excluded were clinical trials, reviews, letters, conference abstracts, case reports and studies involving patients with mixed Crohn’s disease.Data extraction and synthesis Two independent reviewers extracted data and recorded it in Excel. Quality assessment was performed using the Newcastle-Ottawa scale. Meta-analysis was performed using random-effects models due to high heterogeneity across studies.Results 19 studies containing a total of 2612 patients were included. Meta-analysis revealed that clinical response rates were 58% at week 8, 61% at weeks 12–16, 51% at weeks 24–26 and 51% at week 52. Clinical remission rates were 39% at week 8, 43% at weeks 12–16, 40% at weeks 24–26 and 43% at week 52. Corticosteroid-free clinical remission rates were 33% at week 8, 37% at weeks 12–16, 32% at weeks 24–26 and 40% at week 52.Conclusion This meta-analysis of real-world studies indicates that treatment of UC with tofacitinib is associated with favourable clinical response and remission rates in the induction and maintenance phases.https://bmjopengastro.bmj.com/content/11/1/e001347.full |
| spellingShingle | Chuan Wan Chien-Hung Lin Wen-Sheng Liu Hsin-Hui Wang Effectiveness of tofacitinib in patients with ulcerative colitis: an updated systematic review and meta-analysis of real-world studies BMJ Open Gastroenterology |
| title | Effectiveness of tofacitinib in patients with ulcerative colitis: an updated systematic review and meta-analysis of real-world studies |
| title_full | Effectiveness of tofacitinib in patients with ulcerative colitis: an updated systematic review and meta-analysis of real-world studies |
| title_fullStr | Effectiveness of tofacitinib in patients with ulcerative colitis: an updated systematic review and meta-analysis of real-world studies |
| title_full_unstemmed | Effectiveness of tofacitinib in patients with ulcerative colitis: an updated systematic review and meta-analysis of real-world studies |
| title_short | Effectiveness of tofacitinib in patients with ulcerative colitis: an updated systematic review and meta-analysis of real-world studies |
| title_sort | effectiveness of tofacitinib in patients with ulcerative colitis an updated systematic review and meta analysis of real world studies |
| url | https://bmjopengastro.bmj.com/content/11/1/e001347.full |
| work_keys_str_mv | AT chuanwan effectivenessoftofacitinibinpatientswithulcerativecolitisanupdatedsystematicreviewandmetaanalysisofrealworldstudies AT chienhunglin effectivenessoftofacitinibinpatientswithulcerativecolitisanupdatedsystematicreviewandmetaanalysisofrealworldstudies AT wenshengliu effectivenessoftofacitinibinpatientswithulcerativecolitisanupdatedsystematicreviewandmetaanalysisofrealworldstudies AT hsinhuiwang effectivenessoftofacitinibinpatientswithulcerativecolitisanupdatedsystematicreviewandmetaanalysisofrealworldstudies |